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Background: A patient with an early diagnosed epilepsy Valproic acid is one of the most widely used antiepileptic
drugs. Hyperammonemic encephalopathy is a rare, but potentially fatal, adverse drug reaction to valproic acid.
Case description: A patient with an early diagnosed epilepsy, treated with valproic acid, experienced an altered
mental state after 10 days of treatment. Valproic acid serum levels were within limits, hepatic function tests were
normal but ammonia levels were above the normal range.
Valproic acid was stopped and the hyperammonemic encephalopathy was treated with lactulose 15 ml twice daily,
metronidazole 250 mg four times daily and L-carnitine 1 g twice daily.
Discussion and evaluation: Monitoring liver function and ammonia levels should be recommended in patients
taking valproic acid. The constraints of the pharmaceutical market had to be taken into consideration and limited
the pharmacological options for this patient's treatment.
Conclusions: Idiosyncratic symptomatic hyperammonemic encephalopathy is completely reversible, but can induce
coma and even death, if not timely detected.
Clinical pharmacists can help detecting adverse drug reactions and provide evidence based information for the
treatment.
Background
Valproic acid (VPA) has been used in clinical practice
since the 60’s, with a relatively favourable safety and effi-
cacy profile. Pancreatitis, hepatotoxicity and teratogenicity
are the most significant adverse drug reactions. Cases of
hyperammonemia are rarely reported as VPA-induced,
probably because this increased level of ammonia in blood
can vary between asymptomatic, with an incidence of
16-52% (Carr & Sherwsbury 2007), and clinically relevant
levels. Symptomatology due to VPA-induced hyperammo-
nemia include: lethargy, impaired consciousness, focal
neurological signs and symptoms and increased seizure
frequency. More rare described symptoms are: aggression,
ataxia, asterixis, vomiting and coma (Carr & Sherwsbury
2007; Labuzetta et al. 2010).
There is no consensus on whether this symptomatol-
ogy has any relationship with plasma concentration of
VPA. Several studies showed that hyperammonenia may
occur with both therapeutic and supratherapeutic con-
centrations of VPA, indicating that other factors may in-
fluence the onset of hyperammonemia. Some authors
suggest that symptoms of encephalopathy may develop
in patients that have been taking VPA previously, with-
out complications (Carr & Sherwsbury 2007).
A case of encephalopathy due to hyperammonaemia
associated with VPA in a patient with therapeutic drug
levels and normal liver function is presented.
Case description
A 60-year-old man, with history of hypertension, dia-
betes mellitus, and alcoholism (in recovery), is admitted
because of sudden episode of altered state of conscious-
ness preceded by involuntary movements of the left
upper limb, lasting less than five minutes, without motor
asymmetries or sphincter incontinence. Neurological
examination was normal, except for slowness of speech
and difficulty in fixing attention. Vascular study revealed
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no significant changes and the electroencephalogram
(EEG) showed no paroxysmal activity. Considering these
results, the presumptive diagnosis of focal cryptogenic
epilepsy was given. Patient was treated and discharged
with VPA extended release 500 mg twice daily, esome-
prazol 40 mg/day and insulin.
Three days after discharge (10th day of valproic acid),
the patient was readmitted because of disorientation,
speech slowness, somnolence and hemifacial myoclonus.
Adherence to treatment and no use of alcohol were con-
firmed by family members.
Symptoms were interpreted as uncontrolled epilepsy
due to quantitative inefficacy (presumptive prolonged
post-ictal state), and two days after VPA dosage was aug-
mented to 1000 mg twice daily. Symptoms worsened.
Medical tests revealead blood dyscrasias, glicemia
330 mg/dL and normal liver function. Serum electro-
lytes, creatinine, blood urea nitrogen and bilirubin
were also normal. Serum concentration of total val-
proic acid was therapeutic (75 mg/L, therapeutic range:
50–100 mg/L).
Idiosyncratic possibilities were considered. Venous serum
ammonia level was determined ranging 62,1 μmol/L (nor-
mal reference: 5–32 μmol/L) and a repeat EEG showed a
generalized slowing with frequent frontocentral diphasic
sharp waves, suggesting a metabolic encephalopathy. VPA
was stopped and the clinical pharmacist was consulted for
evidence based information. A search strategy formulation
for Medline/Pubmed was applied: “valproic acid/toxicity”
[Mesh]; “Hyperammonemia” [Mesh]. A National Medicines
Information Centre was also consulted. Reviews and case
reports were used. Critical Appraisal Skills Program was ap-
plied for critical analysis of literature (available in: http://
www.phru.nhs.uk/casp/critical_appraisal_tools.htm).
Treatment was initiated with lactulose 15 ml twice
daily (and adjusted to achieve two-three soft stools/
day), L-carnitine 1 g twice daily, metronidazol 250 mg
four times daily, complex B vitamins and levetiracetam
500 mg twice daily. Patient improved his consciousness
state within 24 hours. Past 11 days ammonia level was
7,1 μmol/L and his level of consciousness resolved.
Adjustment in diabetes therapy was made and he was
discharged after 2 more days.
Discussion and evaluation
Symptomatic hyperammonemia due to VPA is quite
rare, but can be fatal (Carr & Sherwsbury 2007). In
the clinical case presented, the patient experienced de-
creased level of consciousness, confusion, disorientation
and slowness of speech. The hemifacial myoclonus that
occurred in three occasions was considered as seizures
in a context of uncontrolled epilepsy.
Pharmacological causes of the hyperammonemia
induced by VPA have not yet been fully clarified. Studies
suggest a hepatic and renal role: amino acids are
degraded in the liver to produce ammonia (Cash et al.
2010). Ammonia is both excreted in the urine and con-
verted in urea, which is the major mechanism of nitro-
gen excretion. Urea is produced in the liver and then
transported to the kidneys where it is excreted in the urine
or via the intestines where is converted in carbon dioxide
and ammonia by the urease-producing bacteria (Labuzetta
et al. 2010). Any change in this process may compromise
the urea cycle and induce hyperammonemia. In the kidney,
VPA affects the renal uptake of glutamine increasing the
ammonia production (Carr & Sherwsbury 2007; Cuturic &
Abramson 2005). Deficiency of L-carnitine may also de-
crease urea formation and increase ammonia accumulation
in the liver (Cash et al. 2010).
Ammonia levels in the brain are normally two times
higher than in the arterial blood, and in case of an acute
rise of blood ammonia this ratio goes up, amplifying the
toxicity of ammonia. The increased level of ammonia in
the central nervous system leads to a higher production
and accumulation of glutamine within the astrocytes,
causing increased intracellular osmolarity, cerebral
oedema and astrocyte dysfunction (Carr & Sherwsbury
2007; Cash et al. 2010).
Although treatment with VPA is generally associated
with asymptomatic hyperammonemia there are possible
risk factors that can induce and worsen symptomatology:
urea cycle disorders, poor nutrition or catabolic state,
L-carnitine deficiency, infancy (immature liver function),
polymedication, especially other antiepileptic and psy-
chotropic substances. Some well known drug associa-
tions that act as risk factors are VPA with: phenytoin;
phenobarbital; carbamazepine; topiramate; clozapine and
risperidone (Carr & Sherwsbury 2007). In most reported
cases patients have concomitant risk medication, and
symptoms develop within days or weeks with abnormal
liver function (Yee et al. 2005). In this case, patient was tak-
ing no medication reported as potential risk factor and hep-
atic tests were normal. The analysis with the Naranjo
probability scale revealed that the adverse drug reaction
was probably caused by VPA (Naranjo et al. 1981).
No formal protocol exists for managing these clinical
situations, but it is consensual that the first procedure
must be the discontinuation of VPA. Usually the pharma-
cological treatment applied is the same as for hepatic en-
cephalopathy, combined with drugs that may interact
with the mechanism of action of VPA (L-carnitine) (Carr
& Sherwsbury 2007; Stewart 2008).
Nonabsorbable disaccharides are considered the stand-
ard of care for hepatic encephalopathy and include lactitol
and lactulose, the latter being the most frequently used
(Cash et al. 2010; Naranjo et al. 1981). Lactulose is meta-
bolized into acetic and lactic acids, resulting in acidi-
fication of the gastrointestinal lumen. This acidification
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inhibits the production of ammonia by the coliform bac-
teria in the intestine. Usually the dosage applied in these
cases is 30 ml of lactulose 2 to 4 times a day, adjusting to
achieve 2 to 4 soft stools a day and patient compliance
(Shiano 2010).
Because we also want to decrease the production of am-
monia in the intestine, antibiotics directed to ammonia-
producing bacteria can be used. Neomycin, rifaximin and
metronidazol have been used (Shiano 2010). Rifaximin has
good efficacy with less bacterial resistance and adverse
effects than the other antibiotics, and thereby probably
more cost-effective (Shiano 2010; Neff 2010).
For this patient, besides treatment with lactulose, the
option of using rifaximin and neomycin had to be dis-
carded because rifaximin is not included in our hospital
formulary and neomycin does not exist on the national
market and has to be imported. For this reason we used
metronidazole. Vitamin B complex supplement was
added because of previous habits of alcohol intake and
levetiracetam was chosen for its profile of safety and effi-
cacy on focal epilepsy. Literature evidence and availabil-
ity of medicines on the Portuguese market were
considered when deciding the treatment options.
Conclusion
Idiosyncratic hyperammonemic encephalopathy without
liver failure is rare, completely reversible, but one of the
most severe, potentially fatal, adverse drug reactions to
VPA. Intermittent confusional episodes due to hyperam-
monemia can be easily mistaken with partial seizures in-
ducing medication error, prompting the physician to
increase the dose of VPA and thus worsening the hyper-
ammonemia. Recommendations to monitor both liver
function and serum ammonia must be considered in
patients taking VPA to assist in the early detection of ad-
verse effects. Clinical pharmacists can play an important
role in this area, recommending the best treatment avail-
able, considering the constraints of the pharmaceutical
market, and providing patient follow-up, with evidence
based information.
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